CCNU, vinblastine, and delalutin therapy in renal cell carcinoma

Gerald J. Vosika, Michael J. Ryan, Ignacio A. Fortuny, Cynthia Meyer, David T. Kiang, Athanasios Theologides, Byrl J. Kennedy

Research output: Contribution to journalArticle

1 Scopus citations


Advanced renal cell carcinoma is relatively resistant to most adequately evaluated chemotherapeutic agents. The combination of CCNU and vinblastine, which has antitumor activity in a frog renal carcinoma model system, has demonstrated activity in initial studies in man. The current study investigated this combination of drugs together with a progestational agent, Delalutin. Seventeen patients with metastatic renal cell carcinoma were treated with CCNU, vinblastine and Delalutin. There were no objective responses. Four patients with stable disease had a mean survival of 18 months compared to 13 patients with progressive disease who had a mean survival of 5 months. The survival of the four patients with stable disease was in large part due to the slowly progressive natural history of their disease.

Original languageEnglish (US)
Pages (from-to)89-91
Number of pages3
JournalMedical and Pediatric Oncology
Issue number1
StatePublished - 1978


  • CCNU
  • Delalutin
  • chemotherapy
  • hypernephroma
  • vinblastine

Fingerprint Dive into the research topics of 'CCNU, vinblastine, and delalutin therapy in renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Vosika, G. J., Ryan, M. J., Fortuny, I. A., Meyer, C., Kiang, D. T., Theologides, A., & Kennedy, B. J. (1978). CCNU, vinblastine, and delalutin therapy in renal cell carcinoma. Medical and Pediatric Oncology, 5(1), 89-91.